Trial Profile

A Phase I, Multicenter, Open-label Study of Oral ABL001 in Patients With Chronic Myelogenous Leukemia (CML) or Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 13 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Asciminib (Primary) ; Dasatinib (Primary) ; Imatinib (Primary) ; Nilotinib (Primary)
Indications Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions; First in man
Sponsors Novartis Pharmaceuticals

12 Dec 2023 Results (n=115) assessing Efficacy, Safety, and Tolerability of Asciminib (ASC) Monotherapy in Patients (Pts) with Philadelphia Chromosome Positive Chronic Myeloid Leukemia in Chronic Phase presented at the 65th American Society of Hematology Annual Meeting and Exposition
12 Dec 2023 Results (cutoff:Mar 14, 2023),presented at the 65th American Society of Hematology Annual Meeting and Exposition
21 Mar 2023 Status changed from active, no longer recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com